A B S T R A C T Flaujeac trait plasma resembled Hageman trait or Fletcher trait, in that the intrinsic coagulation pathway, plasma fibrinolytic pathway, kinin-forming system, permeability factor of dilution (PF/dil) phenomenon were abnormal. The defect in each assay was reconstituted by a factor separable from Hageman factor or Fletcher factor. This substance was an a-globulin with an approximate mol wt of 170,000. Flaujeac plasma did not release a kinin upon incubation with kallikrein and was deficient in total kininogen antigen. Antiserum to kininogen inhibited the activity of the factor in solution. Flaujeac factor was identified as a kininogen of high molecular weight (HMW-kininogen).
INTRODUCTION
Since the first description of Hageman trait as a coagulation factor deficiency (1) , evidence has accumulated to show that Hageman factor participates in other reactions as well. These reactions include the plasma fibrinolytic pathway (2, 3) , the kinin-forming system (4) , and the generation of permeability reactions upon dilution of plasma, a phenomenon recognized by Miles Received for puiblicationt 23 May 1975 and in revised formn 29 Augutst 1975. associates (5, 6 ) and attributed to a plasma globulin (PF/dil). ' In 1972, a second defect in the early-reacting components of the intrinsic coagulation pathway, known as Fletcher trait (7), was found to demonstrate abnormalities similar to those of Hageman factor deficiency (8) .
Fletcher trait was established as the lack of biologic activity of plasma prekallikrein (8, 9) . It is inherited as an autosomal recessive defect.
Lacombe et al. (10, 11) have recently recognized the deficiency of yet another procoagulant, participating in the "contact phase" of coagulation. The deficiency was observed in an asymptomatic French Caucasian woman born of a consanguineous marriage. This report extends that work and demonstrates reduced fibrinolysis, kininformation, and generation of PF/dil. Experiments are described which show that Flaujeac trait (identified by the surname of the proposita) represents the deficiency of human plasma kininogens and is inherited as an autosomal recessive defect. Of the two forms of plasma kininogen that were deficient in Flaujeac plasma, one, high mol wt (HMW-) kininogen, reconstituted each of the deficits of this unusual plasma.
METHODS
Reagents and chemicals. Synthetic bradykinin (BRS 640, Sandoz Ltd., Basel, Switzerland), hexadimethrine bromide (Polybrene, Aldrich Chemical Co., Inc., Milwaukee, Wis.) and Ionagar No. 2 (Colab Laboratories Inc., Chicago Heights, Ill.) were purchased from their suppliers. Rabbit brain cephalin, a platelet substitute in coagulation assays, was obtained from Sigma Chemical Co. (St. Louis, Mo.).
Human plasmas. Blood was obtained by venipuncture from the proposita, Mme. Flaujeac, and four of her children. lAbbrezqations used in this paper: ACD, acid citrate dextrose; APTT, activated partial thromboplastin time; HMW-, high molecular weight; LMW-, low molecular weight; PF/dil, permeability factor of dilution; PTA, plasma thromboplastin antecedent, Factor XI.
Nine parts blood was mixed with one part 3.8%1 citrate or acid-citrate dextrose (ACD anticoagulant (Table I ). The addition of 12.5% normal plasma to Flaujeac plasma gave full correction of the APTT (Fig. 1) . Concentrations of normal plasma less than 12.5% gave a linear dose-response relationship.
In contrast, the minimum concentrations of normal plasma that fully corrected Hageman factor-deficient plasma or Fletcher factor-deficient plasma were approximately 50 and 1.5% respectively (Fig. 1) .
Mixtures of Flaujeac plasma with reference plasmas with deficient activity of Hageman factor, Fletcher factor, or PTA (Factor XI) gave mutual correction of the APTT (Table I) . By a reference plasma one-stage assay method, the content of Hageman factor in the proposita's plasma was 70-90%. The content of Fletcher factor was 65-70%. Although preincubation of Fletcher factor-deficient plasma for 10 min with kaolin led to (Table II) . Therefore, the substance missing in Flaujeac plasma and required for the plasma fibrinolytic pathway differed from Hageman factor or Fletcher factor (prekallikrein).
Absence of kaolin-indutced kinin generation in Flaujeac plasmtia. Neither Flaujeac trait plasma nor Hage- to correct coagulation factor-deficient plasmas (Fig. 4) A factor that corrected the APTT of Flaujeac plasma eluted in an identical position of Fletcher trait, Hageman trait, and normal plasma. Hageman trait plasma was subjected to zone electrophoresis in Pevikon at pH 8.6. At completion of electrophoresis, the block was cut in 1-cm segments, proteins were eluted from each segment, and fractions were assayed for the ability to correct the APTT of Flaujeac plasma. A symmetrical peak of Flaujeac factor activity was identified as an a-globulin, which was distinct from fractions that contained Fletcher factor (Fig. 5) .
The a-globulin fractions that contained Flaujeac factor were concentrated 20-fold by ultrafiltration on a Diaflow PM 30 membrane (Amicon Corp., Lexington, Mass.) to 1.5 ml. To a 0.15-ml sample, 0.05 ml 50% sucrose was added for polyacrylamide disc gel electrophoresis. Upon completion of electrophoresis, the gel was cut in 1.3-mm segments with a gel cutter and eluted in 0.15 M sodium chloride buffered with 0.01 M Tris, pH 7.4. Under these conditions, the Flaujeac factor was recovered in the region of the P-globulins (Fig. 6) Fig. 9 . A (lose-relatedI correction is seeni in the range of 1.5-26%-of the normiial contenit of added factor. Simiilarlv, the ability of HM\NV-kininogen to correct the eniglobulin lxsis timiie after kaolin activation is del)icted in Table IV. WN e investigated the possibility that a fragment of H1NMV-kininog-en. i.e., hradvkinin., mlioht slhor-tenl thle Af'TT. 5 ,g-syntletic bradvkinin wvas added to the in1-cuibationi mi.xture just before, or at the elnd of, the 3-mimill activation wvitlh kaolin. The mlixturl-e was tlhen recalcifie(d and the clottillg timiie recorided. Bradvklinin, despite its presence in a 10-fold excess of the maximum quantity generated by normal plasma, did not influence the APTT. Inhibition of Flautjeac factor with antiserum to kininogen. We studied the ability of sheep antiserum to kininogen to inhibit the clotting time of Flaujeac factor in solution. Normal sheep serum and kininogen antiserum contained Flaujeac factor, and this was removed (see Methods). Flaujeac factor, partially purified by passage over Sephadex G-200, was inhibited in the solution by the addition of antiserum to kininogen, whereas nonimumne sheep globulin was not inhibitory (Fig. 10) .
Kininogens in childrent of tihe proposita. Total plasma kininogen (HMW-kininogen and LMW-kininogen) was measured by electroimmunodiffusion in the proposita and four of her children. The results were compared with HMWV-kininogen assayed by APTT, as shown in Table V .
DISCUSSION
Lacombe and her co-workers described a patient with a new deficiency in the contact phase of the intrinsic coagulation pathway. They systematically excluded all known coagulation factors as responsible for the prolonged APTT (10, 11) . Additionally, they recognized an abnomality of the plasma fibrinolytic pathway. The data reported here confirm these earlier observations and extend them to reveal defects in kinin generation and the permeability phenomenon of Miles and co-workers (5, 6) . In this way, Flaujeac trait, named after the asymptomatic French Caucasian proposita, resembled Hageman trait and Fletcher trait. However, it is distinguished from them by the quantity of normal plasma required for full correction of the APTT, (about 12%) and the failure to normalize the APTT upon prolonged incubation with kaolin (13) . The findings reported herein lead to the conclusion (22) . It will be important to restudy the activation of PTA (8, 23) in light of our present data.
Much more work is needed to clarify the role of HMW-kininogen in the complex plasma pathways dependent upon its function.
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ADDENDUM
After this work was completed and submitted in abstract form (24) , two additional instances of a similar coagulation defect were reported by Waldmann and Abraham (25) and by Colman and his co-workers (26) . We have exchanged plasma samples with these workers and have learned that mutual correction of the activated PTT test did not occur when Flaujeac trait plasma was mixed with plasma from patients identified as Fitzgerald (25) and Williams (26) , suggesting the identity of the same functional deficiency in these three individuals.
Through the courtesy of Drs. H. Kato, Y. N. Han, and S. Iwanaga, we have been able to test highly purified bovine kininogens in Flaujeac plasma (data to be published). Bovine HMW-kininogen corrected the activated PTT of Flaujeac plasma in a dose dependent manner, while bovine LMW-kininogen did not give correction.
